Sen. Maria Cantwell

Maddy summaryThis bill increases the Child and Dependent Care Tax Credit for eligible taxpayers. It raises the maximum credit rate from 35% to 50% (with income phaseouts), doubles the annual dollar limits from $3,000/$6,000 to $8,000/$16,000 for one/two or more dependents, and makes the credit refundable for qualifying taxpayers. The credit becomes refundable, meaning families can receive payments even if they owe no income tax. The bill also includes automatic annual inflation adjustments starting in 2025 to maintain the credit's value. It directly benefits working families with childcare costs, particularly those earning between $125,000 and $400,000 in adjusted gross income.

Maddy summarySRES 523 is a Senate resolution honoring the late Senator Herb Kohl of Wisconsin. The resolution expresses the Senate's sorrow at his death, directs the Secretary of the Senate to communicate it to the House of Representatives and send a copy to his family, and instructs the Senate to adjourn as a mark of respect. This procedural resolution does not create new laws or affect policy, but formally commemorates Kohl's service and legacy. It was introduced by a bipartisan group of Senators and passed unanimously on January 11, 2024.

Maddy summaryThis bill establishes a federal right for patients to access fertility treatments without unreasonable restrictions, protects health care providers who offer these services, and requires insurance coverage for such treatments. It guarantees patients the right to continue ongoing treatments under written agreements and retain control over reproductive materials. States cannot impose requirements that are more burdensome than those for comparable medical procedures or that don’t significantly advance safety. Violations can be challenged in federal court by the government, patients, or providers, while states may still enforce health/safety regulations that are necessary and least restrictive.

Maddy summaryS 993, the Combating Illicit Xylazine Act, makes the illicit distribution and use of xylazine illegal under federal drug laws. The bill defines xylazine broadly (including multiple chemical variants) and prohibits all human use or non-lici distribution, while allowing only veterinary and pharmaceutical uses approved under existing regulations. It requires the DEA and FDA to report to Congress within a year on xylazine's spread and impacts, with a follow-up report four years later. This directly affects drug traffickers and distributors adding xylazine to illicit drugs like fentanyl, aiming to address a public health threat linked to severe health consequences including necrosis.

Maddy summaryThis bill requires the National Oceanic and Atmospheric Administration (NOAA) to modernize its Weather Radio All Hazards network (NWR). It directs NOAA to upgrade existing systems to expand coverage - especially in rural, underserved, and National Park areas - while improving reliability and maintenance. Key provisions include transitioning from outdated copper infrastructure to more reliable telecom systems, enhancing software for county-level weather alerts, and developing backup plans for service outages. The modernization aims to ensure NWR remains a dependable emergency alert source for the public during weather events.

Maddy summaryS 1414, the National Weather Service Communications Improvement Act, requires the National Weather Service (NWS) to replace its internal messaging system (NWSChat) with a commercial cloud-based solution by October 1, 2027. The new system must be publicly hosted, scalable for future growth, user-friendly, and similar to widely used commercial platforms. The bill specifies that implementation must use existing NOAA funding, with no new appropriations authorized. This change directly affects NWS personnel who rely on internal communications for weather forecasting and public safety operations.

Maddy summaryThis Senate resolution (SRES 510) expresses the Senate's support for respecting the FDA's scientific determination that mifepristone - a medication used for early pregnancy termination - is safe and effective. It calls for abortion care policies to be "equitable and based on science," emphasizing the FDA's authority to regulate the drug without interference, including its 2023 update allowing mail-order access. The resolution directly addresses the impact of state restrictions on medication abortion, noting that such policies disproportionately affect Black and Indigenous people, people of color, low-income individuals, rural communities, and other marginalized groups. As a non-binding resolution, it does not change laws but urges alignment with FDA science to protect access to this time-sensitive care.

Maddy summaryThe Children and Teens' Online Privacy Protection Act (S 1418) strengthens privacy protections for children under 13 and teens aged 12-17 online. It requires websites, apps, and connected devices that target children or teens, or are reasonably likely to be used by them, to obtain verifiable consent from parents for children and from teens themselves for those aged 12-17 before collecting personal information. The bill prohibits targeted marketing to children and teens, establishes a "Digital Marketing Bill of Rights for Teens," and creates a Youth Privacy and Marketing Division within the Federal Trade Commission to enforce these rules. It also sets out specific Fair Information Practices Principles requiring transparency, data accuracy, security, and proper data disposal for children's and teens' personal information.

Maddy summaryThe TRANQ Research Act of 2023 directs the National Institute of Standards and Technology (NIST) to fund research on detecting xylazine - a tranquilizer sometimes found in illicit drugs - and other emerging substances. NIST must develop faster testing methods, create public data tools for identifying these drugs, and collaborate with universities, nonprofits, and federal labs to improve detection capabilities and safety practices. The bill requires NIST to report on its progress to Congress within one year. This research initiative aims to enhance scientific tools for drug analysis without imposing new regulations or affecting the public directly.

Maddy summaryThe Pharmacy Benefit Manager Transparency Act of 2023 requires pharmacy benefit managers (PBMs) to disclose pricing information and prohibits them from keeping profit margins between what they charge health plans and what they pay pharmacies. It mandates annual reporting to the Federal Trade Commission about pricing differences, rebates, and formulary changes, and prohibits PBMs from arbitrarily reducing pharmacy reimbursements or increasing fees. The law affects PBMs, health plans, pharmacies, and drug manufacturers by requiring full transparency in drug pricing practices. It includes whistleblower protections for employees who report violations and establishes enforcement mechanisms through the FTC. This legislation aims to increase clarity in the prescription drug pricing system and reduce hidden costs for consumers and healthcare providers.